Introduction {#sec1}
============

Wilms tumor, a malignant kidney tumor in children, currently has achieved a high survival rate in different geographical regions \[[@B1],[@B2]\]. It is reported that approximately 98% of Wilms tumor are sporadic \[[@B3]\]; and approximately 80 percent of Wilms tumor patients are diagnosed before 5 years old \[[@B4]\]. Molecular genetics studies showed that Wilms tumor had a complex etiology involving genetic lesions in the multiple sites \[[@B5],[@B6]\]; and various gene polymorphisms play pivotal roles in the occurrence of Wilms tumor. However, there remain numerous functional single nucleotide polymorphisms (SNPs) in oncogenes and tumor suppressor genes, whose roles in Wilms tumor susceptibility need to be clarified.

As we know, gene mutation is a crucial factor in the tumorigenesis of Wilms tumor. For example, mutations in the coding sequence of the *p53* gene were found in Wilms tumor patients by several research groups \[[@B7],[@B8]\]. Apart from that, Slade et al. \[[@B9]\] showed that translocation t(5;6)(q21;q21), leading to the inactivation of the *HACE1* gene, predisposed Wilms tumor. Moreover, over the past decade, many genes have been found to be involved in the development of Wilms tumor, including *MYCN* \[[@B10]\], *CTNNB1* \[[@B11]\], *WTX* \[[@B12]\], *CHEK2* \[[@B6]\], *BARD1* \[[@B13]\], *hOGG1* and *FEN1* gene \[[@B14]\] and *KRAS* \[[@B15]\].

MicroRNAs are recognized as endogenous non-coding RNAs that can play different biological roles by targeting related genes \[[@B16]\]. In addition, microRNAs are considered promising biomarkers for their stability and ease of detection \[[@B17]\]. *miR34b/c*, a recognized tumor-suppressor gene, was found to be methylated in a variety of tumors \[[@B18]\]. Among the mir-34 family, *miR34b/c* has a stronger ability to inhibit tumor growth, which not only enhanced the attachment of tumor cells, but also inhibited the growth and invasion of cells \[[@B19]\]. On one hand, *miR34b/c* is a mediator of the P53 signaling network and on the other hand, *TP53* can regulate the transcription of *miR34b/c* \[[@B20]\]. The rs4938723 T\>C polymorphism, situated in the *miR34b/c* promoter region, influenced the expression of *miR34b/c* by affecting the binding efficiency of GATA-X transcription factor \[[@B21]\].

*TP53* is a tumor suppressor, which inhibits tumorigenesis mainly by regulating gene transcription \[[@B22]\]. Mutations in *TP53* are common in the most cancer types and have been the focus of various research groups. The *TP53* can facilitate DNA repair by stalling the cell cycle in the G~1~ phase when DNA damage occurs \[[@B23]\]. Moreover, Franken et al. \[[@B24]\] reported that the expression of p53 protein was positively correlated with tumor invasion. *TP53* rs1042522 C\>G polymorphism, the polymorphic variant in *TP53* codon 72, has been shown to be associated with susceptibility to a variety of tumors. *miR34b/c* cooperates with *TP53* to control tumorigenesis. In the *TP53*-deficient cells, *miR34b/c* can overexpress to compensate the functions of p53, such as the regulation of senescence and apoptosis \[[@B25]\]. However, the combined effects of *miR34b/c* rs4938723 T\>C and *TP53* rs1042522 C\>G on Wilms tumor susceptibility remained unclarified. Thus, we conducted the present study to explore the association of *miR34b/c* rs4938723 T\>C and *TP53* rs1042522 C\>G polymorphisms with Wilms tumor risk.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

In the present study, we recruited 183 Wilms tumor patients and 603 cancer-free volunteers from Yuying Children's Hospital of Wenzhou Medical University and Guangzhou Women and Children's Medical Center \[[@B26],[@B27]\]. The age, gender, and clinical stage of all participants are detailed in Supplementary Table S1. At the time of recruitment, all participants or their patients signed informed consent forms. In addition, this investigation was performed with the permission of the Institutional Review Boards of the Yuying Children's Hospital of Wenzhou Medical University and Guangzhou Women and Children's Medical Center.

SNP selection and genotyping {#sec2-2}
----------------------------

In this research, we selected two most frequently investigated SNPs in *miR34b/c* and *TP53* (*miR34b/c* rs4938723 and *TP53* rs1042522 polymorphisms) to investigate their associations with Wilms tumor susceptibility. TaqMan method was used for genotyping \[[@B28]\]. In addition, negative controls were included in genotyping. In order to ensure the accuracy of genotyping, we blindly took 10% samples for repeated testing, and the results were 100% consistent.

Statistical analysis {#sec2-3}
--------------------

The Hardy--Weinberg equilibrium (HWE) of control subjects was estimated by a goodness-of fit χ^2^ test. The logistic regression analysis was performed. Adjusted odds ratios (ORs) as well as 95% confidence intervals (CIs) were used to assess the correlation of *miR34b/c* rs4938723 and *TP53* rs1042522 polymorphisms with Wilms tumor risk. We considered the difference to be statistically significant only when *P*\<0.05.

Results {#sec3}
=======

Correlation of *miR34b/c* rs4938723 and *TP53* rs1042522 polymorphisms with Wilms tumor susceptibility {#sec3-1}
------------------------------------------------------------------------------------------------------

The detailed results are summarized in the [Table 1](#T1){ref-type="table"}. Both the polymorphisms were in agreement with the HWE (*P*=0.459 for the *miR34b/c* rs4938723 T\>C polymorphism, *P*=0.533 for the *TP53* rs1042522 C\>G polymorphism). In our result, for *miR34b/c* rs4938723, the carriers with TC (adjusted OR = 0.73, 95% CI = 0.51--1.06, *P*=0.097) or CC (adjusted OR = 1.42, 95% CI = 0.83--2.43, *P*=0.202) genotypes showed no significant association with Wilms tumor risk compared with carriers of the TT genotype. Besides, no significant association was found between rs4938723 and Wilms tumor risk under the additive (adjusted OR = 1.02, 95% CI = 0.79--1.32, *P*=0.880), dominant (adjusted OR = 0.85, 95% CI = 0.60--1.19, *P*=0.345) or recessive models (adjusted OR = 1.63, 95% CI = 0.98--2.73, *P*=0.061). For *TP53* rs1042522, the carriers with CG (adjusted OR = 1.51, 95% CI = 1.00--2.29, *P*=0.051) or GG (adjusted OR = 1.11, 95% CI = 0.66--1.85, *P*=0.700) genotypes showed no significant association with Wilms tumor risk compared with carriers of the CC genotype. Besides, no significant association was found between rs1042522 and Wilms tumor risk under the additive (adjusted OR = 1.07, 95% CI = 0.84--1.37, *P*=0.584), dominant (adjusted OR = 1.39, 95% CI = 0.93--2.06, *P*=0.109) or recessive models (adjusted OR = 0.84, 95% CI = 0.55--1.28, *P*=0.416). In summary, neither of the two selected polymorphisms showed significant association with Wilms tumor risk.

###### Association between *miR34b/c* rs4938723 T\>C and *TP53* rs1042522 C\>G polymorphisms with Wilms tumor susceptibility

  Genotype                                Cases (*n*=170)   Controls (*n*=600)   *P*[^1^](#T1TFN1){ref-type="table-fn"}   Crude OR (95% CI)   *P*     Adjusted OR (95% CI)[^2^](#T1TFN2){ref-type="table-fn"}   *P*[^2^](#T1TFN2){ref-type="table-fn"}
  --------------------------------------- ----------------- -------------------- ---------------------------------------- ------------------- ------- --------------------------------------------------------- ----------------------------------------
  miR34b/c rs4938723 T\>C (HWE = 0.459)                                                                                                                                                                         
  TT                                      86 (50.59)        279 (46.50)                                                   1.00                        1.00                                                      
  TC                                      60 (35.29)        266 (44.33)                                                   0.73 (0.51--1.06)   0.098   0.73 (0.51--1.06)                                         0.097
  CC                                      24 (14.12)        55 (9.17)                                                     1.42 (0.83--2.42)   0.205   1.42 (0.83--2.43)                                         0.202
  Additive                                                                       0.881                                    1.02 (0.79--1.32)   0.881   1.02 (0.79--1.32)                                         0.880
  Dominant                                84 (44.91)        321 (53.50)          0.346                                    0.85 (0.60--1.19)   0.346   0.85 (0.60--1.19)                                         0.345
  Recessive                               146 (85.88)       545 (90.83)          0.060                                    1.63 (0.98--2.72)   0.062   1.63 (0.98--2.73)                                         0.061
  TP53 rs1042522 C\>G (HWE = 0.533)                                                                                                                                                                             
  CC                                      39 (22.94)        175 (29.17)                                                   1.00                        1.00                                                      
  CG                                      98 (57.65)        291 (48.50)                                                   1.51 (1.00--2.29)   0.052   1.51 (1.00--2.29)                                         0.051
  GG                                      33 (19.41)        134 (22.33)                                                   1.11 (0.66--1.85)   0.704   1.11 (0.66--1.85)                                         0.700
  Additive                                                                       0.102                                    1.07 (0.84--1.36)   0.587   1.07 (0.84--1.37)                                         0.584
  Dominant                                131 (77.06)       425 (70.83)          0.110                                    1.38 (0.93--2.06)   0.111   1.39 (0.93--2.06)                                         0.109
  Recessive                               137 (80.59)       466 (77.67)          0.415                                    0.84 (0.55--1.28)   0.415   0.84 (0.55--1.28)                                         0.416

χ^2^ test for genotype distributions between Wilms tumor patients and controls.

Adjusted for age and gender.

Stratification analysis {#sec3-2}
-----------------------

We then analyzed the correlation of *miR34b/c* rs4938723 and *TP53* rs1042522 polymorphisms with Wilms tumor susceptibility in subgroups stratified by age, gender and clinical stage ([Table 2](#T2){ref-type="table"}). However, no significant association was observed.

###### Stratification analysis of risk genotypes with tumor susceptibility

  Variables         rs4938723 (cases/controls)   OR (95% CI)   *P*                 AOR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   rs1042522 (cases/controls)   OR (95% CI)   *P*      AOR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}                       
  ----------------- ---------------------------- ------------- ------------------- ------------------------------------------------- ---------------------------------------- ---------------------------- ------------- -------- ------------------------------------------------- ---------------------------------------- ------------------- -------
  Age, months                                                                                                                                                                                                                                                                                                                                    
    ≤18             64/247                       9/21          1.65 (0.72--3.79)   0.234                                             1.64 (0.71--3.75)                        0.244                        11/80         59/188   1.79 (0.95--3.40)                                 0.073                                    1.77 (0.94--3.36)   0.079
    \>18            82/298                       15/34         1.60 (0.83--3.09)   0.157                                             1.63 (0.85--3.15)                        0.143                        25/95         72/237   1.15 (0.69--1.93)                                 0.584                                    1.16 (0.69--1.93)   0.579
  Gender                                                                                                                                                                                                                                                                                                                                         
    Female          67/244                       9/21          1.56 (0.68--3.57)   0.291                                             1.56 (0.68--3.57)                        0.291                        21/79         55/186   1.11 (0.63--1.96)                                 0.713                                    1.11 (0.63--1.96)   0.712
    Male            79/301                       15/34         1.68 (0.87--3.24)   0.121                                             1.68 (0.87--3.24)                        0.121                        18/96         76/239   1.70 (0.96--2.99)                                 0.067                                    1.70 (0.96--2.99)   0.067
  Clinical stages                                                                                                                                                                                                                                                                                                                                
    I+II            58/545                       7/55          1.20 (0.52--2.75)   0.673                                             1.25 (0.54--2.88)                        0.606                        15/175        50/425   1.37 (0.75--2.51)                                 0.304                                    1.38 (0.75--2.52)   0.300
    III+IV          75/545                       13/55         1.72 (0.90--3.29)   0.103                                             1.73 (0.90--3.31)                        0.102                        22/175        66/425   1.24 (0.74--2.07)                                 0.420                                    1.23 (0.74--2.06)   0.431

Adjusted for age and gender, without the corresponding stratifying factor.

AOR: adjusted odds ratio

Combined effect analysis {#sec3-3}
------------------------

As shown in the [Table 3](#T3){ref-type="table"}, no statistically significant association was detected in the combined effect analysis. However, the individuals with both *miR34b/c* rs4938723 TC genotype and *TP53* rs1042522 CC genotype might have a borderline significantly decreased risk of Wilms tumor (adjusted OR = 0.51, 95% CI = 0.25--1.01, *P*=0.053).

###### The association of combined genotypes of *miR34b/c* rs4938723 T\>C and *TP53* rs1042522 C\>G polymorphisms with Wilms tumor risk

  Genotypes   Cases (*n*=170)   Controls (*n*=600)   OR (95% CI)   *P*                 AOR (95% CI)[^1^](#T3TFN1){ref-type="table-fn"}   *P*[^1^](#T3TFN1){ref-type="table-fn"}   
  ----------- ----------------- -------------------- ------------- ------------------- ------------------------------------------------- ---------------------------------------- -------
  TT          CC                22 (12.94)           89 (14.83)    1.00                                                                  1.00                                     
  TT          CG                46 (27.06)           128 (21.33)   0.95 (0.57--1.58)   0.828                                             0.95 (0.57--1.59)                        0.837
  TT          GG                18 (10.59)           62 (10.33)    0.76 (0.40--1.47)   0.417                                             0.77 (0.40--1.47)                        0.425
  TC          CC                14 (8.24)            73 (12.17)    0.50 (0.25--1.01)   0.052                                             0.51 (0.25--1.01)                        0.053
  TC          CG                35 (20.59)           137 (22.83)   0.67 (0.39--1.15)   0.147                                             0.67 (0.39--1.15)                        0.148
  TC          GG                11 (6.47)            56 (9.33)     0.52 (0.24--1.10)   0.086                                             0.52 (0.24--1.10)                        0.087
  CC          CC                3 (1.76)             13 (2.17)     0.61 (0.16--2.26)   0.456                                             0.61 (0.16--2.27)                        0.461
  CC          CG                17 (10.00)           26 (4.33)     1.72 (0.83--3.55)   0.143                                             1.73 (0.84--3.57)                        0.140
  CC          GG                4 (2.35)             16 (2.67)     0.66 (0.21--2.10)   0.479                                             0.66 (0.21--2.10)                        0.476

Obtained in logistic regression models with adjustment for age and gender.

Discussion {#sec4}
==========

We conducted this case--control study to explore the correlation of *miR34b/c* rs4938723 and *TP53* rs1042522 polymorphisms with Wilms tumor risk. No significant association was found in the single locus and stratified analyses. However, the combine effect analysis suggests that the combination of these two gene polymorphisms may have a potential influence on Wilms tumor susceptibility.

To our knowledge, the association between *miR34b/c* and Wilms tumor susceptibility has not been investigated. *miR34b/c* has been shown to be intimately connected to the development and prognosis of a variety of tumors, including gastric cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, neuroblastoma and many others \[[@B31]\]. In our previous study, we found that *miR34b/c* rs4938723 T\>C polymorphism has a protective effect on neuroblastoma \[[@B36]\]. Sato et al. \[[@B37]\] reported that *miR34b/c* methylation in circulating DNA could be used to predict disease progression in malignant pleural mesothelioma patients. Moreover, in a meta-analysis, *miR34b/c* gene polymorphism was shown to increase the risk of gastric cancer and liver cancer while decreasing the risk of esophageal squamous cell carcinoma and colorectal cancer \[[@B38]\].

*TP53* rs1402522 is one of the most investigated *TP53* gene polymorphisms. However, we found no significant association between the *TP53* rs1402522 polymorphism and Wilms tumor risk. A study by Liu et al. \[[@B39]\] revealed that the effect of *TP53* rs1402522 polymorphism on Wilms tumor risk is very weak, which is consistent with our result. Another study conducted by Fu et al. \[[@B40]\] also showed no significant association between *TP53* rs1402522 polymorphism and Wilms tumor risk, and they found that CG/GG genotypes carriers significantly increased Wilms tumor risk in children younger than 18 months of age, compared with CC genotype carriers. Moreover, it is reported that *TP53* rs1042522 may not confer susceptibility to cancers, such as neuroblastoma \[[@B41]\], retinoblastoma \[[@B42]\]. *miR34b/c* is involved in the *TP53* pathway, and their 'double hit' (methylation of *miR34* and *TP53* mutations) has been shown to affect survival in a variety of tumors \[[@B43]\]. The negative result in the current study might result from the small sample size.

Several limitations should be addressed. First, in the process of tumorigenesis, the interaction among various gene polymorphisms is very complex. Only selecting two gene polymorphisms might lead to false-negative results. Second, we did not recruit enough participants for the present study. The sample size might not be adequate to detect real association if it is weak. Third, all the recruiters were from Guangzhou and Wenzhou. As a result, selection bias might exist. Our results should be explained with caution.

In summary, our statistical results showed that the association of *miR34b/c* rs4938723 and *TP53* rs1042522 polymorphisms with Wilms tumor susceptibility was not statistically significant. Our findings require validation in the studies with larger sample size.
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